Gilead Sciences Stock Outlook: Is Wall Street Bullish or Bearish?

With a market cap of $159.9 billion, Gilead Sciences, Inc. (GILD) is a global biopharmaceutical company that discovers, develops, and commercializes medicines addressing unmet medical needs across areas such as HIV, liver diseases, cancer, and infectious diseases. It offers a broad portfolio of treatments and collaborates with multiple organizations to advance innovative therapies worldwide.

Shares of the Foster City, California-based company have underperformed the broader market over the past 52 weeks. GILD stock has increased 22.6% over this time frame, while the broader S&P 500 Index ($SPX) has gained 28.4%. However, the stock has risen 6.4% on a YTD basis, outpacing SPX's 4.5% return.